Format

Send to

Choose Destination
Clin Infect Dis. 2018 Jun 29. doi: 10.1093/cid/ciy525. [Epub ahead of print]

Rapid and Extensive Expansion in the U.S. of a New Multidrug-Resistant Escherichia coli Clonal Group, Sequence Type ST1193.

Author information

1
Department of Microbiology, University of Washington School of Medicine, Seattle, WA, USA.
2
ID Genomics, Inc., Seattle, WA, USA.
3
Keck School of Medicine of USC, Los Angeles, CA, USA.
4
Langone Hospital of NYU, New York, NY, USA.
5
Children's Hospital, Seattle, WA, USA.
6
Department of Microbiology and Harborview Medical Center, University of Washington School of Medicine, Seattle, WA, USA.
7
Kaiser Permanente Washington and Kaiser Permanente Washington Research Institute, Seattle, WA, USA.
8
Kaiser Permanente Washington, Seattle, WA, USA.
9
VA Medical Center and University of Minnesota, Minneapolis, MN, USA.

Abstract

We describe the rapid and ongoing emergence across multiple US cities of a new multidrug-resistant E. coli clone - ST1193, resistant to fluoroquinolones (100%), trimethoprim/sulfamethoxazole (55%) and tetracycline (53%). ST1193 is associated with younger adults (age < 40 years) and currently comprises a quarter of fluoroquinolone-resistant clinical E. coli urine isolates.

PMID:
29961843
DOI:
10.1093/cid/ciy525

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center